此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Adherence to Oral Anticoagulant in Chinese Patients With NVAF (NVAF)

Study of Compliance and Influencing Factors in Chinese Patients With Nonvalvular Atrial Fibrillation (NVAF) to Oral Anticoagulant

Investigate the compliance of oral anticoagulants in Chinese NVAF patients and find out the causes, so as to provide basis for formulating effective measures to improve the compliance of oral anticoagulants.

研究概览

地位

尚未招聘

干预/治疗

详细说明

  1. The general information about these patients was recorded such as gender, age, smoking history, drinking history, heart failure, hypertension, diabetes, coronary heart disease, stroke history, TIA history, peripheral vascular disease, etc. CHA2DS2-VASc score and HAS-BLED score were recorded.
  2. Medication information and follow-up information was collected.For the patients included in the study, the medication records of oral anticoagulants (outpatient, emergency, hospitalization), adverse reactions, anticoagulant use history, drug withdrawal or dressing change, disease changes, etc. within three years were recorded by referring to the patient's medical records.

研究类型

观察性的

注册 (预期的)

500

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:zhang xiaoyu, master
  • 电话号码:18858160685
  • 邮箱:474430517@qq.com

学习地点

    • Zhejiang
      • Hangzhou、Zhejiang、中国、086
        • Chang Cuie
        • 接触:
        • 接触:
        • 首席研究员:
          • huang yuwen, master

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Through the hospital information system (HIS), the information of patients using warfarin, dabigatran and rivaroxaban during 2016.1-2-2021.1 was retrieved

描述

Inclusion Criteria:

NVAF; CHA2DS2-VASc≥2(femal≥3); After starting the medication, the duration of continuous medication was more than 3 months

Exclusion Criteria:

The patients had the records of anticoagulants in other hospitals; Patients lost to follow-up; Patients who do not need long-term anticoagulants after successful radiofrequency ablation or left atrial appendage occlusion. The follow-up time was 3 years or the following conditions occurred: the patient's condition changed and no longer used oral anticoagulants or died, the follow-up was stopped.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
dabigatran group
NVAF patients who taking dabigatran capsule 110mg,bid during 2016.2-2021.1,the duration of continuous medication was more than 3 months.PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran.
PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
Rivaroxaban group
NVAF patients who taking rivaroxaban tablet 15mg,bid during 2016.2-2021.1,the duration of continuous medication was more than 3 months.PDC value and mmas-8 scale were used to evaluate the compliance of patients with dabigatran. PDC value and mmas-8 scale were used to evaluate the compliance of patients with rivaroxaban.
PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin
wafarin group
NVAF patients who taking wafarin tablet during 2016.2-2021.1,the duration of continuous medication was more than 3 months, the dosage is adjusted according to INR. MMAS-8 scale was used to evaluate the compliance of patients with rivaroxaban.evaluate the compliance of patients with wafarin.
PDC value and MMAS-8 scale were used to evaluate the compliance of patients with dabigatran, rivaroxaban and wafarin

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
The long-term compliance of oral anticoagulants in NVAF patients was compared among warfarin group, dabigatran group and rivaroxaban group.
大体时间:6 months
In this study, the eight item Morisky medication adherence scale (MMAS-8) was used to compare the long-term compliance of patients with warfarin, dabigatran axetil and rivaroxaban. The proportion of days covered (PDC) was used to compare the long-term compliance of patients with dabigatran and rivaroxaban.
6 months

次要结果测量

结果测量
措施说明
大体时间
Explore the influence of different factors on patients' compliance, and to find out the factors influencing patients' long-term compliance, so as to provide basis for formulating strategies to improve patients' long-term compliance.
大体时间:6 months
Data of all influencing factors included in CHA2DS2-VASc score scale, such as age hypertension,heart failure, diabetes, women and vascular diseases, as well as region, medical insurance category, education level, anticoagulant use history and HAS-BLED score
6 months
Through multivariate logistic regression analysis, to clarify the impact of various factors on long-term compliance of patients.
大体时间:6 months
Univariate analysis of significant variables, further by multivariate logistic regression analysis
6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:huang yuwen, master、The Second Affiliated Hospital of Medical College of Zhejiang University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年7月20日

初级完成 (预期的)

2022年6月6日

研究完成 (预期的)

2023年6月10日

研究注册日期

首次提交

2021年6月10日

首先提交符合 QC 标准的

2021年6月20日

首次发布 (实际的)

2021年6月29日

研究记录更新

最后更新发布 (实际的)

2021年6月29日

上次提交的符合 QC 标准的更新

2021年6月20日

最后验证

2021年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2020-966

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅